Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 2
2004 1
2005 1
2006 4
2008 1
2009 1
2010 3
2011 2
2012 2
2013 2
2014 2
2015 3
2016 8
2017 5
2018 2
2019 1
2020 1
2022 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

37 results

Results by year

Filters applied: . Clear all
Page 1
Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial.
Mehanna H, Robinson M, Hartley A, Kong A, Foran B, Fulton-Lieuw T, Dalby M, Mistry P, Sen M, O'Toole L, Al Booz H, Dyker K, Moleron R, Whitaker S, Brennan S, Cook A, Griffin M, Aynsley E, Rolles M, De Winton E, Chan A, Srinivasan D, Nixon I, Grumett J, Leemans CR, Buter J, Henderson J, Harrington K, McConkey C, Gray A, Dunn J; De-ESCALaTE HPV Trial Group. Mehanna H, et al. Among authors: buter j. Lancet. 2019 Jan 5;393(10166):51-60. doi: 10.1016/S0140-6736(18)32752-1. Epub 2018 Nov 15. Lancet. 2019. PMID: 30449623 Free PMC article. Clinical Trial.
Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.
Taal W, Oosterkamp HM, Walenkamp AM, Dubbink HJ, Beerepoot LV, Hanse MC, Buter J, Honkoop AH, Boerman D, de Vos FY, Dinjens WN, Enting RH, Taphoorn MJ, van den Berkmortel FW, Jansen RL, Brandsma D, Bromberg JE, van Heuvel I, Vernhout RM, van der Holt B, van den Bent MJ. Taal W, et al. Among authors: buter j. Lancet Oncol. 2014 Aug;15(9):943-53. doi: 10.1016/S1470-2045(14)70314-6. Epub 2014 Jul 15. Lancet Oncol. 2014. PMID: 25035291 Clinical Trial.
EGFR inhibitors in lung cancer.
Buter J, Giaccone G. Buter J, et al. Oncology (Williston Park). 2005 Nov;19(13):1707-11; discussion 1711-2, 1720-3. Oncology (Williston Park). 2005. PMID: 16425523 Free article. Review.
The EGFRvIII transcriptome in glioblastoma: A meta-omics analysis.
Hoogstrate Y, Ghisai SA, de Wit M, de Heer I, Draaisma K, van Riet J, van de Werken HJG, Bours V, Buter J, Vanden Bempt I, Eoli M, Franceschi E, Frenel JS, Gorlia T, Hanse MC, Hoeben A, Kerkhof M, Kros JM, Leenstra S, Lombardi G, Lukacova S, Robe PA, Sepulveda JM, Taal W, Taphoorn M, Vernhout RM, Walenkamp AME, Watts C, Weller M, de Vos FYF, Jenster GW, van den Bent M, French PJ. Hoogstrate Y, et al. Among authors: buter j. Neuro Oncol. 2022 Mar 12;24(3):429-441. doi: 10.1093/neuonc/noab231. Neuro Oncol. 2022. PMID: 34608482 Free PMC article.
Disease outcome and associated factors after definitive platinum based chemoradiotherapy for advanced stage HPV-negative head and neck cancer.
de Roest RH, van der Heijden M, Wesseling FWR, de Ruiter EJ, Heymans MW, Terhaard C, Vergeer MR, Buter J, Devriese LA, de Boer JP, Navran A, Hoeben A, Vens C, van den Brekel M, Brakenhoff RH, Leemans CR, Hoebers F. de Roest RH, et al. Among authors: buter j. Radiother Oncol. 2022 Oct;175:112-121. doi: 10.1016/j.radonc.2022.08.013. Epub 2022 Aug 13. Radiother Oncol. 2022. PMID: 35973619 Free article.
Impact of chemotherapy on the outcome of osteosarcoma of the head and neck in adults.
Boon E, van der Graaf WT, Gelderblom H, Tesselaar ME, van Es RJ, Oosting SF, de Bree R, van Meerten E, Hoeben A, Smeele LE, Willems SM, Witjes MJ, Buter J, Baatenburg de Jong RJ, Flucke UE, Peer PG, Bovée JV, Van Herpen CM. Boon E, et al. Among authors: buter j. Head Neck. 2017 Jan;39(1):140-146. doi: 10.1002/hed.24556. Epub 2016 Aug 10. Head Neck. 2017. PMID: 27507299 Free PMC article.
The impact of different volumetric thresholds to determine progressive disease in patients with recurrent glioblastoma treated with bevacizumab.
Gahrmann R, Smits M, Vernhout RM, Taal W, Kapsas G, de Groot JC, Hanse M, Vos M, Beerepoot LV, Buter J, Flach ZH, van der Holt B, van den Bent M. Gahrmann R, et al. Among authors: buter j. Neurooncol Adv. 2022 Mar 9;4(1):vdac032. doi: 10.1093/noajnl/vdac032. eCollection 2022 Jan-Dec. Neurooncol Adv. 2022. PMID: 35419519 Free PMC article.
37 results